Vera Therapeutics Statistics
Share Statistics
Vera Therapeutics has 63.77M
shares outstanding. The number of shares has increased by 16.54%
in one year.
Shares Outstanding | 63.77M |
Shares Change (YoY) | 16.54% |
Shares Change (QoQ) | 0.67% |
Owned by Institutions (%) | 99.99% |
Shares Floating | n/a |
Failed to Deliver (FTD) Shares | 20,819 |
FTD / Avg. Volume | 2.04% |
Short Selling Information
The latest short interest is 6.08M, so 9.6% of the outstanding
shares have been sold short.
Short Interest | 6.08M |
Short % of Shares Out | 9.6% |
Short % of Float | 12.81% |
Short Ratio (days to cover) | 5.33 |
Valuation Ratios
The PE ratio is -15.38 and the forward
PE ratio is -8.06.
Vera Therapeutics's PEG ratio is
-0.69.
PE Ratio | -15.38 |
Forward PE | -8.06 |
PS Ratio | 0 |
Forward PS | 1.8 |
PB Ratio | 4.05 |
P/FCF Ratio | -17.25 |
PEG Ratio | -0.69 |
Financial Ratio History Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Vera Therapeutics.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 25.67,
with a Debt / Equity ratio of 0.09.
Current Ratio | 25.67 |
Quick Ratio | 25.67 |
Debt / Equity | 0.09 |
Debt / EBITDA | -0.33 |
Debt / FCF | -0.4 |
Interest Coverage | 21.92 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | n/a |
Profits Per Employee | $-1,358,464.29 |
Employee Count | 112 |
Asset Turnover | 0 |
Inventory Turnover | n/a |
Taxes
Income Tax | 1K |
Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -51.07% in the
last 52 weeks. The beta is 1.28, so Vera Therapeutics's
price volatility has been higher than the market average.
Beta | 1.28 |
52-Week Price Change | -51.07% |
50-Day Moving Average | 25.07 |
200-Day Moving Average | 36.41 |
Relative Strength Index (RSI) | 42.8 |
Average Volume (20 Days) | 1,020,478 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -167.17M |
Net Income | -152.15M |
EBITDA | -167.17M |
EBIT | -159.77M |
Earnings Per Share (EPS) | -2.75 |
Full Income Statement Balance Sheet
The company has 92.65M in cash and 54.64M in
debt, giving a net cash position of 38.01M.
Cash & Cash Equivalents | 92.65M |
Total Debt | 54.64M |
Net Cash | 38.01M |
Retained Earnings | -461.25M |
Total Assets | 655.68M |
Working Capital | 625.85M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -134.68M
and capital expenditures -972K, giving a free cash flow of -135.65M.
Operating Cash Flow | -134.68M |
Capital Expenditures | -972K |
Free Cash Flow | -135.65M |
FCF Per Share | -2.45 |
Full Cash Flow Statement Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |